Volver al Panel









AbbVie Inc. (ABBV)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
ABBV Intraday
No data available
SímboloABBV
Fecha de SalidaJan 2, 2013
CEOMr. Robert A. Michael CPA
Empleados a Tiempo Completo57k
SectorHealthcare
IndustriaDrug Manufacturers - General
PaísUnited States
BolsaNYSE
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | +1.01% | +2.87 US$ |
| 5 Días | -2.92% | -8.61 US$ |
| 1 Mes | +0.57% | +1.62 US$ |
| 6 Meses | +32.78% | +70.72 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de ABBV...
Estadísticas Clave
Cap. de Mercado
505.89B
Relación P/E
49.18
Rend. de Div.
2.44%
Máx. 52 Semanas
$302.93
Mín. 52 Semanas
$190.75
Consenso de Analistas
CONSENSOCompra
ALCISTA2379.3%
NEUTRAL517.2%
BAJISTA13.4%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$237.00
$237.00
Objetivo Máx.
$350.00
$350.00
Actual$286.42
Objetivo Prom.$315.88
Recomendaciones de Analistas
Precio Objetivo:$315.88($237.00 - $350.00)
¿Buscas más valores? Explóralos en el screener
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre ABBV
Únase a la comunidad para compartir su análisis
Últimas Noticias para ABBV

Is Solid Tumor Partnership Altering The Investment Case For AbbVie (ABBV)?
Simply Wall St.•21 nov 2026, 00:12

5 High-Yield Healthcare Stocks for a Tax-Free Roth IRA Income Stream
24/7 Wall St.•20 nov 2026, 17:15

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
Motley Fool•20 nov 2026, 16:20

Should You Buy Jazz Pharmaceuticals Stock For Its Cash?
Trefis•20 nov 2026, 15:27

Senate Passes Landmark Permitting Bill. Here’s Who Could Benefit.
Barrons.com•20 nov 2026, 15:20


Should You Buy Bristol Myers Squibb Stock At Today's Discount?
Trefis•20 nov 2026, 14:51

Jim Cramer Says Cardinal Health Is “the Stock That Is Made for This Moment”
24/7 Wall St.•20 nov 2026, 14:47

AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
PR Newswire•20 nov 2026, 13:00
iShares U.S. Healthcare ETF (IYH) Sells $17.4 Million of Eli Lilly on Wednesday
GuruFocus.com•20 nov 2026, 11:05